REVIEWER

Piero Ruggenenti Head, Division of Nephrology and Dialysis
Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (Italy) REVIEW RETURNED 11-Feb-2019 GENERAL COMMENTS Scolari and coworkers failed to address my previous comments and presented a new version of the manuscript that is substantially identical to the original one.
I have a series of major issues that still need to be addressed and have been ignored:
1. Follow-up duration:
The statement that results of the MENTOR trial have not been published is wrong and it is not at reason to ignore that they have been presented at the ASN Renal Week in 2017 (https://www.medpagetoday.com/meetingcoverage/asn/69092) and full data are available online (https://player.vimeo.com/video/281435713).
The statement that there are no long-term results with the use of rituximab in membranous nephropathy is wrong and unfair. The paper entitled "Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy" (van den Brand JAJG1, J Am Soc Nephrol. 2017 Sep;28(9):2729-2737) compared time to any adverse event (primary outcome); serious or non-serious events; partial and complete remission of the nephrotic syndrome; and a composite of doubling of serum creatinine, ESRD, or death between 100 Rtx-treated patients and 103 patients who received daily St-Cp Patients were monitored with standardized protocols and data adjusted for baseline characteristics by Cox regression. Over a median follow-up of 40 months, the Rtx group had significantly fewer adverse events than the St-Cp group (63 versus 173; P<0.001), both serious (11 versus 46; P<0.001) and non-serious (52 versus 127; P<0.001). Cumulative incidence of any first (35.5% versus 69.0%; P<0.001), serious (16.4% versus 30.2%; P=0.002), or non-serious (23.6% versus 60.8%; P<0.001) event was significantly lower with Rtx Adjusted hazard ratios (95% confidence intervals) between Rtx and St-Cp groups were 0.27 (0.16 to 0.44) for any first adverse event, 0.32 (0.15 to 0.68) for serious adverse events, and 0.23 (0.13 to 0.41) for non-serious adverse events. Efficacy outcomes were similar". In a large, randomized con¬trolled trial (RCT) conducted in the UK [Howman, A. et al. Immunosuppression for progressive membranous nephropathy: a UK randomized controlled trial. Lancet 381, 744-751 (2013)], steroids plus chlorambucil were found to slow the loss of renal func¬tion compared with supportive therapy alone in patients with membranous nephropathy33. However, the 3 year follow up period was too short to evaluate whether treatment also prevented ESRD. Moreover, prednisolone and chlorambucil combination therapy was associated with a nearly twofold higher incidence of SAEs com¬pared with supportive therapy (2.8 events per patient versus 1.5 events per patient). Overall, 36 of the 56 events observed with specific treatment were thought possibly or likely to be treatment-related. Events included two malignancies, 28 cases of bone marrow toxicity, and eight of impaired glucose tolerance. This event rate exceeded the rates reported in previous RCTs of alkylat¬ing agents in membranous nephropathy mentioned by the Authors that were designed and conducted before 1996. In 1996, the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use defined the Guidelines for Good Clinical Practice, including monitoring of SAEs. Before this time, the under-reporting of such events could have contributed to the general underestimation of the risks associated with heavy immunosuppression. Similarly, in countries that formally adopted the guidelines in the past few years, more-recent (post 1996) studies are also likely to be affected by underestimation of adverse events. Even in well conducted trials, adverse events such as lymphomas and other malignant diseases, which can occur as late as 10-20 years after treatment, are likely to be missed. The risk of malignancies and other seri¬ous complicationsincluding post-transplant lymph¬oproliferative disorders, opportunistic infections, and osteomuscular diseaseincreases when patients who progress to ESRD receive a kidney transplant and receive immunosuppressive therapy to prevent graft rejection. Thus, the risk/benefit profile of combination ther¬apy with steroids and chlorambucil is poor, particularly in patients at increased risk of treatment-related SAEs because of kidney function impairment or rapid renal function loss (the majority of patients enrolled in the UK trial). Even in patients with a normal and stable glo¬merular filtration rate, the adverse effects of chlorambu¬cil have led the nephrology community to recommend that chlorambucil should not be used in the treatment of membranous nephropathy. An adequately powered RCT to assess the long-term benefits and risks of com¬bination therapy with steroids and cyclophosphamide would require hundreds of patients to be followed up for 10-20 years, The aforementioned considerations and quoted papers and data that are summarized in a recent review on the treatment of membranous nephropathy (Ruggenenti P, Fervenza FC, Remuzzi G. Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol. 2017 Sep;13(9):563-579) are fully ignored by the authors. Thus, a trial with too short follow up will generate misleading results with potentially adverse impact on everyday patient care and on their healthy and outcome.
Sample size
The considerations about the underpowered design of the trial are ignored. A safety trial could be probably run with the sample size considered by the Authors. An efficacy trial should be at least one order of magnitude larger. Thus, the proposed study with the actual sample size is expected to be inconclusive or misleading.
Inclusion criteria
The dilution effect of including new incident patients without long history of persistent nephrotic syndrome and evidence of no previous spontaneous remission is not addressed. This limitation combined to too short follow up and small sample size will further reduce statistical power and enhance the risk of false positive or negative findings.
REVIEWER
Durga Anil K Kanigicherla
Manchester University Hospitals NHS Manchester UK REVIEW RETURNED 21-Feb-2019
GENERAL COMMENTS
The reviewer completed the checklist but made no further comments.
REVIEWER alfonso otero gonzalez Ourense University Clinical Hospital REVIEW RETURNED 12-Apr-2019
Dr. Scolari et al. designed a project for the treatment of idiopathic membranous glomerulonephritis of "medium risk" and in which the therapeutic options have multiplied (Hofstra J et al., Nature Reviews 9,443,2013) and the project was already widely reviewed by other experts Questions:
1º.-Idiopathic membranous glomerulonephritis of "medium risk" , because it is not expected 6 months and not 3 months, to start active treatment, as indicated by the guidelines? 2º.-No reference is made to the secondary treatment: gastric protector, Pneumocystis jiroveci prophylaxis , osteoporosis prophylaxis, and vaccines.
REVIEWER
Jesse Hsu
University of Pennsylvania, USA REVIEW RETURNED 01-Jul-2019
GENERAL COMMENTS
bmjopen-2019-029232, initial submission Here is a list of specific comments. Note: line numbering in reviews and comments is based on ruler applied in Editorial Manager-generated PDF whereas page numbering in reviews and comments is supplied by authors. 1. Page 5, line 55: The Rationale and justification of the active comparator section was more suitable for the Introduction section.
2.
Page 6, lines 34-47: These sentences were more suitable for the Introduction section.
3.
Page 6, lines 47-60 and page 7, lines 3-9: These sentences contained duplicate information in the Outcomes section.
4.
Page 7, lines 23-25: I suggest to replace "randomized ...therapy)" with 'eligible for the study' because the randomization information will be provided in the Randomization section.
5.
Page 8, lines 31-33: If the Blinding section was not a BMJ Open required section, I would suggest to remove it (duplicate information). 6.
Page 10, lines 3-7: It was not clear why this sentence was in quotations. 7.
Page 10, line 31: Please be more specific about "standard statistical methods" because readers might have different 'standards' in mind.
8.
Page 10, line 37: Please remove the less than symbol. 9.
Page 10, lines 39-41: Please be specific about "methods for continuous, count or survival data". 10.
Page 10, line 44: Shouldn't this mean that 'missing data in both groups will be considered as failures'? 11.
Page 10, line 52: "At least 1 year" was not clear given the study follow-up time was 36 months. 12.
Page 10, lines 52-54: Please specify the participating centers (at least number of centers). 13.
Page 10, lines 54-56: This sentence contradicted the subsequent sentences. I suggest to revise as follows. 'Given that we do not have preliminary information, the study assumes that the remission probability in the rituximab arm is greater than ....' 14.
Page 11, lines 7-9: I think this sentence was true if replacing "if it exists" with 'if the effect is 15 15.
Page 11, lines 31-33: In the Design of the study section, the study period was listed as 36 months. Please clarify what had changed. 16.
Page 11, lines 33-35: Except for the purpose of observational studies, it was not clear how this design could be useful in a randomized setting.
VERSION 1 -AUTHOR RESPONSE
REVIEWER 1, PATRICK H NACHMAN REVIEWER COMMENT ……The remaining comment relates to the description of criteria for "study termination" vs a participant's discontinuation from the treatment arm of the study (without terminating the entire study). On page 11, stating on line 24, the following sentence "Study termination will be mandatory in the following situations: pregnancy, significant worsening of renal function (defined as doubling of serum creatinine), onset of malignancy, serious hypersensitivity or allergic reaction, any serious adverse events, serious intercurrent illness, administrative reasons, or investigator's or participant's request." appears to be an appropriate description of criteria for a participant's discontinuation from the treatment arm of the study -NOT a termination of the entire study.
AUTHOR REPLY
We agree with the reviewer. We have changed the subject of the sentence, which now reads: "Termination of receipt of study drug for a patient will be mandatory in the following situations: pregnancy, significant worsening of renal function (defined as doubling of serum creatinine), onset of malignancy, serious hypersensitivity or allergic reaction, any serious adverse events, serious intercurrent illness, administrative reasons, or investigator's or participant's request."
REVIEWER COMMENT
Minor typographical error:
Page 8 line 49, the words "in order to reduce common reactions" are repeated twice in the same sentence.
AUTHOR REPLY
The repeated words have been removed REVIEWER 2, PIERO RUGGENENTI I have a series of major issues that still need to be addressed and have been ignored:
REVIEWER COMMENT
The statement that results of the MENTOR trial have not been published is wrong………………….
AUTHOR REPLY
The final results of the Mentor trial have been published on the New England Journal Medicine on July 4, 2019. This trial compared Rituximab and oral cyclosporine for 12 months. Patients were followed for 24 months because it is well known that calcineurin inhibitors (which are not the first-line therapy of membranous nephropathy) are associated with a high incidence of relapse after discontinuation (data confirmed by Mentor trial).
In membranous nephropathy, with all the major therapeutic options, the response time usually takes a median time of 7 months (Alfaadhel and Cattran, Kidney Dis 2015;1:126-137). Moreover, remission of proteinuria at 1 year is an accepted surrogate marker for long-term outcome (Thompson et al. JASN 26, 2930 , 2015 . Finally, our secondary analyses will include long-term data.
REVIEWER COMMENT
The statement that there are no long-term results with the use of rituximab in membranous nephropathy is wrong and unfair (???) ….
AUTHOR REPLY
Our statement that there are no long-term results with the use of rituximab in membranous nephropathy is substantiated by literature data. There are no studies with a long-term follow-up (>5 years) that report beneficial effects of Rituximab on hard renal end-points such as doubling of serum creatinine or development of end stage kidney failure.
In the paper entitled "Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy" (van den Brand J, 2017) Rituximab group showed a median follow-up of 40 months (18-60). The study is not a randomized controlled trial, but a historical comparison. Finally, patients treated with Cyclophosphamide received 2 to 4 times the cumulative dose participants of our RCT will receive.
On the other hand, long-term RCTs (10 years) with alkylating agents are available and show the safety of these drugs when given every other month for 6 months.
The UK RCT (Howman et al, Lancet, 2013) showed a higher adverse-event rate when compared with RCTs of alkylating agents we mentioned. However, it is of note that the majority of patients enrolled in UK trial had a baseline kidney function impairment. Toxicity with this specific therapeutic approach has been reported to be substantially increased not only by prolonging its duration (van den Brand J, 2017) but also by selecting patients with impaired kidney function (Howman, 2013) . In addition, the alkylating agent given was chlorambucil (not cyclophosphamide) which is associated with an increased risk of treatment-related SAEs.
In conclusion, alkylating agents remain the only agents proven effective in preventing end stage kidney failure or death. Given their toxicity, they should only be prescribed by experienced physicians, restricted to patients at risk of renal progression and regularly monitored. Other immunosuppressive agents, including Rituximab and cyclosporine, only used proteinuria reduction as the endpoint. The choice of first-line therapy therefore still awaits direct head-to-head trials comparing Rituximab and alkylating agents.
REVIEWER COMMENT
Sample size
The considerations about the underpowered design of the trial are ignored… AUTHOR REPLY
In the manuscript, we clearly stated that we have designed "a pilot RCT that will inform the design of a larger study…". A pilot precedes the main trial to decide how best to conduct a large-scale research. Pilot study is generally small in size, scope, duration and budget. It is of note that the sample size of a pilot study is a matter of controversy debate, and there is little published guidance concerning how large a pilot study should be.
REVIEWER COMMENT
Inclusion criteria
The dilution effect of including new incident patients without long history of persistent nephrotic syndrome and evidence of no previous spontaneous remission is not addressed….
AUTHOR REPLY
We have designed a RCT. Thus, the possibility of spontaneous remission will be equally distributed within the two treatment arms. With respect to the "long history of persistent nephrotic syndrome", the UK RCT mentioned by the Reviewer have raised the concern that late start of immunosuppressive therapy could be less effective than immediate start. REVIEWER 3, DURGA ANIL K KANIGICHERLA, MANCHESTER Nil else to comment REVIEWER 4, ALFONSO OTERO GONZALEZ, OURENSE REVIEWER COMMENT 1…because it is not expected 6 months and not 3 months, to start active treatment, as indicated by the guidelines?
Thank you very much for this comment, which raises an important point. Our decision was based on several considerations: 1. the evidence supporting the KDIGO recommendation that the period of observation before specific treatment may be of 6 months is of low quality (1C).
2. remissions usually occur more frequently in the first few months but they may develop at any time 3. The antiproteinuric effect of RAAS blockers is modest and mainly observed in patients with lower levels of proteinuria 4. The time of onset of nephrotic syndrome usually precedes by several weeks/months the final diagnosis of membranous nephropathy 5. A late start of immunosuppressive therapy could be less effective than immediate start In the Mentor trial (N Engl J Med 2019; 381:36-46) all patients received blockers of the RAAS for 3 months before randomization.
REVIEWER COMMENT
2. No reference is made to the secondary treatment: gastric protector, Pneumocystis jiroveci prophylaxis, osteoporosis prophylaxis, and vaccines.
AUTHOR REPLY
Our protocol does not include secondary treatment in both the active comparator and the intervention arms.
REVIEWER 5, JESSE HSU, UNIVERSITY OF PENNSYLVANIA REVIEWER COMMENTS 1. Page 5, line 55: The Rationale and justification of the active comparator section was more suitable for the Introduction section 2. Page 6, lines 34-47: These sentences were more suitable for the Introduction section.
We appreciate these comments. To address these points, we made changes to the Introduction section, including some sentences of the Rationale and justification of the active comparator section (this section has been eliminated) and some sentences of the Objective section (line 34-37, page 6).
We have also modified the reference 16, since the Mentor trial has been published.
The introduction section now reads:
" Primary Membranous Nephropathy (MN) is a common causes of nephrotic syndrome in adults. MN is an autoimmune disease mediated by the deposition of antibodies (usually IgG4) produced by autoreactive B cells directed against antigens located in the subepithelial area of the glomerular basement membrane. In 60-70% of patients with primary MN the antibodies are directed against the receptor1 of phospholipase A2 (PLA2R) (1,2); in 10% of patients, circulating antibodies against thrombospondin type-1 domain-containing 7A (THSD7A) have been detected (3, 4) . Additional autoantibodies of unknown clinical significance directed to podocyte neo-expressed cytoplasm proteins have been described, including aldose reductase (AR), Mn-superoxide dismutase (SOD2) and alpha-enolase (alpha-ENO) (5).
The disease has heterogeneous outcomes. A complete or partial remission of proteinuria may develop spontaneously in 30-50% of patients (6,7), but relapses may occur and a number of patients will continue to have proteinuria and progress slowly. In longer follow-up studies, (10 years or more), 35-50% of the untreated patients may die or progress to end stage kidney failure (8) (9) (10) (11) . The pathogenetic background of MN suggests that there is a rationale to stop the production of these autoantibodies with therapies targeting B cells. A number of different treatments have been used in MN, including corticosteroids, cyclophosphamide, calcineurin inhibitors and ACTH. Based on evidence from randomized controlled trials of the effect of alternating steroids and alkylating agent on disease remission and long-term progression, the 2012 KDIGO guidelines recommend that initial therapy consist of a 6-month course of alternating monthly cycles steroids and an oral alkylating agent, preferably cyclophosphamide (12).
However, cyclophosphamide use increase the risk of myelotoxicity, infection and cancer. The ideal treatment of MN should target the B cells but display a more favourably safety profile. In the last years, a therapy based on the anti-CD20 monoclonal antibody rituximab has been successfully used in . While a RCT recently showed that that rituximab is non-inferior to cyclosporine (second line therapy) in inducing long-term remission of proteinuria in patients with MN (16) , there is no head-to-head comparison between Rituximab and gold standard treatment (cyclical corticosteroid/cyclophosphamide therapy) for MN. Existing data are insufficient to frame a testable pre-specified hypothesis of superiority or non-inferiority of a new treatment for MN (rituximab) versus standard care of the disease (cyclophosphamide). Data on the proportion of incidence of cases of MN who are eligible for either intervention and are willing to accept to be randomized in a trial are insufficient to design a large RCT addressing intervention decisions. This pilot multicenter RCT will assess the efficacy and safety of treatment with steroids and an alkylating agent versus rituximab in patients with primary MN and heavy proteinuria. This pilot RCT will focus on complete remission of MN which is an important clinical outcome per se and is associated with an excellent long-term renal and patient survival (17). This trial will also provide effect estimates of rituximab versus standard care as well as data on recruitment potential in a multicenter setting.
REVIEWER COMMENT
3. Page 6, lines 47-60 and page 7, lines 3-9: These sentences contained duplicate information in the Outcomes section.
AUTHOR REPLY
We thank the reviewer for this comment. These sentences have been eliminated. Thus, the Objective section has been entirely removed from the manuscript.
REVIEWER COMMENT
4. Page 7, lines 23-25: I suggest to replace "randomized . . . therapy)" with 'eligible for the study' because…..
AUTHOR REPLY
The sentence "will be randomized in a 1:1 ratio to either the intervention arm (rituximab) or the active comparator arm (corticosteroid/cyclophosphamide therapy)" has been replaced by "will be eligible for the study" REVIEWER COMMENT 5. Page 8, lines 31-33: If the Blinding section was not a BMJ Open required section, I would suggest to remove it (duplicate information).
We agree. The Blinding section has been removed REVIEWER COMMENT 6. Page 10, lines 3-7: It was not clear why this sentence was in quotations.
We made a mistake. Quotations have been removed.
REVIEWER COMMENT
7. Page 10, line 31: Please be more specific about "standard statistical methods" because readers might have different 'standards' in mind AUTHOR REPLY We agree. We have changed the sentence which now reads: "We will use standard statistical methods to summarize the sample characteristics overall and by arm assignment, using statistics for quantitative (mean and standard deviation) and qualitative data (frequencies) as appropriate".
8. Page 10, line 37: Please remove the less than symbol.
AUTHOR REPLY
Thank you; removed REVIEWER COMMENT 9. Page 10, lines 39-41: Please be specific about "methods for continuous, count or survival data" AUTHOR REPLY We agree. We have changed the sentence which now reads: "We will use logistic regression to study other binary outcomes, and methods for continuous, count or survival data for time-to-event analyses (secondary outcome). In all analyses, we will use an intention-to-treat approach, whereby participants will be analysed as randomized regardless of protocol adherence. We will replace missing data in two ways: first carrying forward the last available measure; second, assuming the worst-case scenario by considering the missing data in the active comparator group as successes and missing data in the active intervention as failures".
REVIEWER COMMENT
10. Page 10, line 44: Shouldn't this mean that 'missing data in both groups will be considered as failures'?
AUTHOR REPLY
Because we do not know, we elected to assume the worse-case scenario as one reference analysis.
REVIEWER COMMENT
11. Page 10, line 52: "At least 1 year" was not clear given the study follow-up time was 36 months.
AUTHOR REPLY
Probability of remission at one year is the main outcome. In other analyses we will consider longer follow-up time.
REVIEWER COMMENT
12. Page 10, lines 52-54: Please specify the participating centers (at least number of centers).
AUTHOR REPLY
The participant centers have been specified in the Setting section (page 7, line 33-34) REVIEWER COMMENT 13. Page 10, lines 54-56: This sentence contradicted the subsequent sentences. I suggest to revise as follows. 'Given that we do not have preliminary information, the study assumes that the remission probability in the rituximab arm is greater than….'
